Business Context and Reporting Period
This Form 8-K Current Report was filed by Cardiff Oncology, Inc. on January 18, 2022. The report primarily serves to disclose new clinical data regarding the Company's lead program, onvansertib, and to announce an upcoming investor presentation.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on clinical developments rather than financial performance metrics.
Material Changes
The material event reported is the announcement of new clinical data for onvansertib in combination with standard-of-care (SOC) FOLFIRI/bevacizumab. This treatment targets patients with KRAS-mutated metastatic colorectal cancer (mCRC) in the second-line setting. The data is scheduled for presentation as a poster at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) on January 22, 2022.
Guidance, Outlook, and Management Commentary
- Investor Presentation: Management plans to present to investors at 5:00 pm ET on January 18, 2022.
- Regulatory Disclosure: The information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
- Exhibits: The filing includes a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2) containing further details.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific efficacy and safety data points regarding onvansertib.
- Examine the corporate presentation (Exhibit 99.2) for updated clinical timelines and strategic outlook.
- Verify the Company's cash runway and liquidity status in the most recent 10-Q or 10-K, as this 8-K does not contain financial statements.
- Monitor the ASCO-GI symposium on January 22, 2022, for the formal poster presentation by Dr. Heinz-Josef Lenz.